The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis

To the Editor: Older adults can comprise up to 13% of patients with atopic dermatitis (AD).1 Therefore, clinical trials of AD therapeutics need to adequately include adults over the age of 65 years to ensure that they are treated with medications, the safety and efficacy of which have been explicitly evaluated in their age group. Unfortunately, older adults are often underrepresented in clinical trials across numerous diseases,2,3 including those of systemic AD therapies (azathioprine, methotrexate, and mycophenolate mofetil).